Newly developed retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is creating considerable excitement within the weight loss community. Early clinical research have shown significant reductions in physical weight and gains in health markers for people with obesity . Researchers believe this novel approach could sig